📋 Tender Overview
Contract awarded for Centralized framework agreement for 24 months for the supply of medicines xiii/2024 { "detected_language": "romanian", "translated_text": "lot-0012, title: betaderm type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0019, title: captopril 25 mg type combinations ®, captopril lph 25 mg ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0036, title: enalapril 10 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0042, title: esomeprazole type combinations -40mg- powder for solution injection/perfusion or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0052, title: gentamicin sulphate type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0056, title: indomethacin 50 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0067, title: xefo rapid 8 mg type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0068, title: lornoxicam 8 mg/2 ml type combinations ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0073, title: meloxicam rompharm 15 mg/1.5 ml type combinations ®, movalis ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0115, title: tobrom ® type combinations or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0119, title: dexatobrom sol. oft. ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum quantities both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications - chapter 9. lot-0121, title: tralgit 50 mg type combinations ®, tramag ® or equivalent, description: the product description, minimum and maximum quantities, both under the framework agreement and under the subsequent contract, as well as the estimated values can be found in the specifications. according to the specifications, the minimum and maximum estimated value excluding vat: 96.40 ron.Centralized framework agreement for 24 months for the supply of medicines xiii/2024
